Clinical Research Directory

Inclusion Criteria: * adult patient suffering from haematological malignancy * followed in the clinical hematology department or in the hematology day hospital of the Grenoble Alps University Hospital * consenting to carrying out CYP2C19 genotyping * likely to start treatment with voriconazole (for curative or prophylactic purposes as part of care) * having signed a written consent to participate * affiliated to a social security system Exclusion Criteria: * comedication with strong inhibitors/inducers (valproic acid, phenytoin, carbamazepine, rifampicin) * Subject during exclusion period from another study, * Persons referred to in articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant woman, parturient woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons subject to care psychiatric pursuant to articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, persons admitted to a health or social establishment for purposes other than research , minors, person subject to a legal protection measure or unable to express their consent)